Vol. 1 No. 6 (2021)
Reimbursement Recommendations

Fedratinib (Inrebic)

Published June 21, 2021

Key Messages

  • Clinical evidence suggests that the JAK inhibitor Inrebic should be reimbursed as a treatment option for adults with myelofibrosis who cannot take or tolerate Jakavi. Inrebic cannot be prescribed to those who progress on Jakavi.
  • There is insufficient evidence to justify a cost premium for Inrebic over other JAK inhibitors reimbursed for the treatment of myelofibrosis.
  • If Inrebic is not reimbursed by public payers, best available therapy will be the only other treatment option for patients who cannot take Jakavi.